Cargando…

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs

PURPOSE: Hepatic encephalopathy (HE) is a recurrent severe complication of progressive hepatic cirrhosis. The aim of this study is to evaluate the average annual direct healthcare costs for the treatment of patients with overt HE in Italy. PATIENTS AND METHODS: This retrospective, observational stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roggeri, Daniela Paola, Roggeri, Alessandro, Rossi, Elisa, Cinconze, Elisa, Gasbarrini, Antonio, Monici Preti, PierAlessandro, De Rosa, Marisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506032/ https://www.ncbi.nlm.nih.gov/pubmed/26203290 http://dx.doi.org/10.2147/HMER.S87594

Ejemplares similares

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri, Daniela Paola, et al.
Publicado: (2017)

Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study
por: Roggeri, Daniela Paola, et al.
Publicado: (2016)

Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study
por: Roggeri, Alessandro, et al.
Publicado: (2014)

A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results
por: Joppi, Roberta, et al.
Publicado: (2015)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues
por: Roggeri, Alessandro, et al.
Publicado: (2016)

Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy
por: Tognella, Silvia, et al.
Publicado: (2021)

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study
por: Roggeri, Daniela Paola, et al.
Publicado: (2014)

Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
por: Faccioli, Jessica, et al.
Publicado: (2023)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Anti-NMDA and Anti-AMPA Receptor Antibodies in Central Disorders: Preclinical Approaches to Assess Their Pathological Role and Translatability to Clinic
por: Olivero, Guendalina, et al.
Publicado: (2023)

Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests
por: Ehrenbauer, Alena F., et al.
Publicado: (2023)

Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis
por: Gairing, Simon J., et al.
Publicado: (2023)

Somatostatin, a Presynaptic Modulator of Glutamatergic Signal in the Central Nervous System
por: Pittaluga, Anna, et al.
Publicado: (2021)

Animal Naming Test – a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy
por: Agarwal, Ankit, et al.
Publicado: (2020)

Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs
por: Seghieri, Chiara, et al.
Publicado: (2022)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Overt Hepatic Encephalopathy Experienced by Individuals With Cirrhosis: A Qualitative Interview Study
por: Ladegaard Grønkjær, Lea, et al.
Publicado: (2018)

Neuroprotective Effect of Nortriptyline in Overt Hepatic Encephalopathy Through Attenuation of Mitochondrial Dysfunction
por: Jeong, Ji Heun, et al.
Publicado: (2018)

The Role of Presepsin in Diagnosing Infections in Patients with Liver Cirrhosis and Overt Hepatic Encephalopathy
por: Igna, Razvan, et al.
Publicado: (2022)

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2022)

Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update
por: Olivero, Guendalina, et al.
Publicado: (2020)

Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720
por: Roggeri, Alessandra, et al.
Publicado: (2023)

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2019)

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy
por: Abe, Kazumichi, et al.
Publicado: (2021)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

Altered Modular Organization of Functional Connectivity Networks in Cirrhotic Patients without Overt Hepatic Encephalopathy
por: Zheng, Gang, et al.
Publicado: (2014)

Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy
por: Yang, Zhe-Ting, et al.
Publicado: (2018)

Validation of a Simple Quality‐of‐Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy
por: Lauridsen, Mette Munk, et al.
Publicado: (2020)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
por: Oey, Rosalie C., et al.
Publicado: (2019)

Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization
por: Bai, Zhaohui, et al.
Publicado: (2019)

Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis
por: Wernberg, Charlotte W., et al.
Publicado: (2019)

Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis
por: Wu, Xiu, et al.
Publicado: (2015)

Abnormal corpus callosum induced by overt hepatic encephalopathy impairs interhemispheric functional coordination in cirrhosis patients
por: Kuang, Yangying, et al.
Publicado: (2021)

Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
por: Yang, Yang, et al.
Publicado: (2021)

Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation
por: Alabsawy, Eman, et al.
Publicado: (2022)

Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy
por: Pandico, Fulvio, et al.
Publicado: (2023)

Anomalous Gray Matter Structural Networks in Patients with Hepatitis B Virus-Related Cirrhosis without Overt Hepatic Encephalopathy
por: Lv, Xiao-Fei, et al.
Publicado: (2015)

Characterization of brain microstructural abnormalities in cirrhotic patients without overt hepatic encephalopathy using diffusion kurtosis imaging
por: Sun, Qing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hgp6202md03pbsbb51u3onm98e